Phase II funding BEL recently secured 2.2M in Phase II funding from the National Institutes of Aging to conduct an FDA-monitored clinical trial, signaling substantial credibility and potential for long-term partnerships in clinical research, medical devices, and sleep-related neuroscience solutions.

Clinical trial potential The ongoing FDA-monitored trial of Electric Sleep Therapy targeting deep sleep and memory in seniors with Mild Cognitive Impairment presents opportunities to license, co-develop, or supply compatible sensing hardware, data analytics platforms, and regulatory-compliant infrastructure.

SBIR driven innovation BEL’s origin within SBIR-funded activities and its focus on exploring new technologies position it as a collaborator for government-funded R&D programs, pilot projects, and early-stage medical device innovations seeking SBIR or similar support.

Clinical research ecosystem Historical ties to University of Oregon and transitions through EGI/Philips create a networked potential for university-affiliated trials, training collaborations, and access to clinical research sites, driving multi-site feasibility and data collection opportunities.

Tech and compliance readiness BEL’s tech stack and regulatory-aligned clinical ambitions indicate readiness to partner for digital health data management, patient monitoring solutions, and compliant software or hardware integrations leveraging existing platforms and standards.